Real Time Touch

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)

Real Time Touch

Sanofi Pasteur patents

Recent patent applications related to Sanofi Pasteur. Sanofi Pasteur is listed as an Agent/Assignee. Note: Sanofi Pasteur may have other listings under different names/spellings. We're not affiliated with Sanofi Pasteur, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "S" | Sanofi Pasteur-related inventors

Concomitant dengue and yellow fever vaccination

The present invention relates to a yellow fever (yf) vaccine for use in a method for inducing a protective immune response against yellow fever, wherein said method comprises concomitantly administering said yellow fever vaccine to a human subject together with a tetravalent dengue vaccine which comprises a live attenuated dengue virus of each of serotypes 1 to 4. This invention also pertains to a tetravalent dengue vaccine which comprises a live attenuated dengue virus of each of serotypes 1 to 4 for use in a method of inducing a protective immune response against yellow fever, wherein said method comprises concomitantly administering said tetravalent dengue vaccine to a human subject together with a yellow fever (yf) vaccine.. ... Sanofi Pasteur

Methods of use of influenza vaccine for prevention of pneumonia

This application relates to the field of prevention of pneumonia by administration of a high-dose influenza vaccine.. . ... Sanofi Pasteur

Methods of optimizing nucleotide sequences encoding engineered influenza proteins

The disclosure provides methods for generating an optimized nucleotide sequence encoding an engineered influenza structural protein and the optimized nucleotide sequences obtained therefrom. The optimized nucleotide sequences can be used in a reverse genetics system to facilitate the rescue of infectious influenza virus containing the engineered structural proteins and/or enhance viral titers. ... Sanofi Pasteur

Multivalent meningococcal polysaccharide-protein conjugate vaccine

The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. ... Sanofi Pasteur

Neisseria meningitidis trypsin-like serine protease polypeptides and compositions thereof

The present invention relates to novel polypeptides derived from neisseria meningitidis proteins, in particular auto-transporters of the trypsin-like serine protease subclass, such as iga1p, app and ausi, and their use in immunogenic compositions i.a., vaccine compositions for the prevention and/or treatment of meningococcal infections. In particular, it provides fragments of iga1p, app and ausi and polypeptides comprising or consisting of these fragments and fusions thereof, which may be used in immunogenic compositions, for example vaccine compositions.. ... Sanofi Pasteur

Meningitidis vaccines comprising subtilinases

The present invention relates to novel polypeptides derived from meningitis proteins, in particular auto-transporters of the subtilinase subclass, and their use in vaccines and vaccine compositions for the prevention and/or treatment of meningitis and meningococcal infections.. . ... Sanofi Pasteur

Compositions comprising n. meningitidis proteins

The invention relates to immunogenic compositions comprising at least two neisseria meningitidis (nm) protein antigens selected from the group consisting of a trypsin-like serine protease auto-transporter antigen such as igai p, app or ausi antigen, a nalp antigen and a tbpb antigen. Preferably, the composition of the invention comprises (i) the trypsin-like serine protease auto-transporter antigen and (ii) the nalp antigen and/or tbpb antigen.. ... Sanofi Pasteur

Icp0-mediated enhanced expression system

Methods and compositions for increasing the production of recombinant proteins by introducing icp0 to cells capable of producing a recombinant protein are encompassed. In one method, the recombinant protein is a protein that is required for the replication of a replication defective virus, wherein the recombinant protein is provided to the replication defective virus in trans.. ... Sanofi Pasteur

Multimerization of recombinant protein by fusion to a sequence from lamprey

The present invention relates to polymerized recombinant proteins, to recombinant nucleic acids coding for the polymerized recombinant proteins, to expression cassettes comprising the recombinant nucleic acids, to host cells transformed by the expression cassettes and to a method for multimerizing a recombinant protein. The polymerized proteins of the invention may be used in pharmaceutical or immunogenic compositions. ... Sanofi Pasteur

Meningococcal vaccine based on lipooligosaccharide (los) originating from modified neisseria meningitidis strains of immunotype l6

The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by neisseria meningitidis especially of serogroup b. To this end, the invention in particular provides a lipooligosaccharide (lqs) of n. ... Sanofi Pasteur

Toxoid, compositions and related methods

The disclosure relates to generally to the field of toxin inactivation. More specifically, it relates to clostridial toxins, methods of inactivating these toxins and compositions (e.g., vaccines) comprising toxoids (e.g., produced by these methods). ... Sanofi Pasteur

Pharmaceutical compositions containing clostridium difficile toxoids a and b

This invention relates to compositions including clostridium difficile toxins and/or toxoids and corresponding methods. The compositions of the invention include one or more excipients that increase stability and/or decrease aggregation of the toxins.. ... Sanofi Pasteur

Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza

The present invention provides co-administration (for example, immunogenic cocktail compositions and/or prime-boost regimens) of computationally optimized h1n1 influenza hemagglutinin (ha) polypeptides. Co-administration of the optimized h1n1 influenza hemagglutinin (ha) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to diverse and multiple h1n1 influenza virus strains, including both seasonal and pandemic strains.. ... Sanofi Pasteur

Novel immunogenic formulations comprising linear or branched polyacrylic acid polymer adjuvants

The present invention provides for novel immunological and vaccine formulations comprising a newly applied non-crosslinked polyacrylic acid polymer adjuvant. The adjuvants may be combined with a wide variety of immunogens to produce vaccines that are safe and effective when administered to a wide range of target animals. ... Sanofi Pasteur

11/16/17 / #20170326221

Detoxification method for lipopolysaccharide (lps) or lipid a of gram-negative bacteria

The invention relates to a method of detoxifying a lipopolysaccharide (lps) or a lipid a from a gram-negative bacterium, which comprises mixing the lps or the lipid a with a cationic lipid so as to form a complex in which the lps or the lipid a is associated with the cationic lipid. According to the conventional preparation modes, the cationic lipid with the co-lipid, if this latter is present, get(s) structured into complexes i.a. ... Sanofi Pasteur

10/26/17 / #20170304426

Vaccine compositions against dengue virus diseases

The present invention relates to vaccine compositions that are useful in a method of protecting a human subject against dengue disease.. . ... Sanofi Pasteur

10/26/17 / #20170304423

Compositions and methods for immunizing against c. difficile

This disclosure relates to methods for eliciting an immune response against c. Difficile toxin a and toxin b in an adult human subject. ... Sanofi Pasteur

08/03/17 / #20170219283

Liquid feeding device for the generation of droplets

The present invention provides, inter alia, for a liquid feeding device for the generation of droplets, in particular for the use in a process line for the production of freeze-dried particles, with a droplet ejection section for ejecting liquid droplets in an ejection direction, the droplet ejection section comprising at least one inlet port for receiving a liquid to be ejected, a liquid chamber for retaining the liquid, and a nozzle for ejecting the liquid from the liquid chamber to form droplets, wherein the liquid chamber is restricted by a membrane on one side thereof, the membrane being vibratable by an excitation unit, wherein the longitudinal axis of the liquid chamber is tilted relative to the longitudinal axis of the nozzle, and/or the liquid feeding device further comprises a deflection section for separating the droplets from each other by means of at least one gas jet, wherein the deflection section gas jet intersects perpendicular with an ejection path of the liquid ejected from the liquid chamber.. . ... Sanofi Pasteur

07/27/17 / #20170211111

Method for producing haemophilus influenzae type b antigens

The invention concerns a method for producing, on an industrial scale, capsular polysaccharide of haemophilus influenzae type b (prp) intended for vaccine purposes, according to which a strain of haemophilus influenzae type b (hib) is cultured in a culture medium, the culture supernatant is harvested and treated in order to extract the capsular polysaccharide therefrom, said culture medium comprising at least: —one source of carbon, —protoporphyrin, —salts, —amino acids, —nad or nadh, —vitamins, —means for regulating the ph, characterised in that said culture medium is chemically defined.. . ... Sanofi Pasteur

06/08/17 / #20170157233

Immunogenic compositions

This disclosure relates to immunogenic compositions comprising an isolated immunogenic s. Pneumoniae pcpa polypeptide, at least one additional antigen (such as for example, an isolated immunogenic s. ... Sanofi Pasteur

05/04/17 / #20170121373

Expression and conformational analysis of engineered influenza hemagglutinin

The present invention provides, among other things, compositions and methods for analyzing the expression and conformation of engineered influenza hemagglutinin in particular, the present invention provides methods of screening in silico designed ha antigens using neutralizing antibody panels specific to conserved epitopes. In some embodiments, the has are down selected for inclusion in universal influenza vaccines based upon their binding to neutralizing antibody panels in immunostaining assays.. ... Sanofi Pasteur

04/13/17 / #20170102385

Assay for diagnosing streptococcus pneumoniae

Assays for detecting anti-streptococcal antibodies in biological samples using one or more streptococcal antigens are described herein. Various combinations of antigens may be used in the assays. ... Sanofi Pasteur

03/09/17 / #20170065710

Immunological compositions

The disclosure relates to immunological compositions for vaccinating human beings against infection by the human immunodeficiency virus (hiv).. . ... Sanofi Pasteur

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009


This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. is not affiliated or associated with Sanofi Pasteur in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Sanofi Pasteur with additional patents listed. Browse our Agent directory for other possible listings. Page by